Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jacob Steiger

Plastic Surgery Within the Head and Neck Boca Raton, FL Medical Doctor

NPI 1982760849 CMS profile 271880

1001 N Federal Hwy, Boca Raton, FL 33432

Open in the dashboard

General payments

$14,188

192 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacob Steiger of Boca Raton, FL is reported in the CMS Open Payments database as having received $14,188 across 192 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Plastic Surgery Within the Head and Neck profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $710 24
2024 General $2,889 28
2023 General $2,829 34
2022 General $2,756 28
2021 General $1,730 35
2020 General $596 10
2019 General $2,679 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacob Steiger
  • Plastic Surgery Within the Head and Neck median
  • Middle half of Plastic Surgery Within the Head and Neck
  • National median

In program year 2025, general payments to Jacob Steiger were reported at $710. Among 103 Plastic Surgery Within the Head and Neck profiles paid that year, the median was $300 and the middle half received between $115 and $580.

Show as a table
Year Jacob Steiger Plastic Surgery Within the Head and Neck median Middle half National median
2019 $2,679 $270 $76–$780 $163
2020 $596 $172 $52–$421 $114
2021 $1,730 $227 $64–$753 $132
2022 $2,756 $338 $112–$800 $149
2023 $2,829 $303 $89–$723 $160
2024 $2,889 $289 $115–$714 $164
2025 $710 $300 $115–$580 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merz North America, Inc. $12,250 83 payments
  2. Galderma Laboratories, L.P. $1,304 87 payments
  3. Revance Therapeutics, Inc. $284 3 payments
  4. Allergan Inc. $220 14 payments
  5. Musculoskeletal Transplant Foundation Inc. $81 2 payments
  6. TELA Bio, Inc. $33 1 payment
  7. Aerin Medical Inc. $16 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,435 190 payments
  2. Travel and Lodging $1,753 2 payments
Products named General payments · program years 2019–2025
  1. Xeomin Dermatology $5,487 36 payments
  2. ASCLERA $2,435 22 payments
  3. Xeomin musculoskeletal $2,102 13 payments
  4. DAXXIFY $284 3 payments
  5. DYSPORT $260 24 payments
  6. BOTOX $172 10 payments
  7. DYSPORT $155 17 payments
  8. OviTex 2S $33 1 payment
  9. Vivaer RF Stylus $16 2 payments
  10. BOTOX COSMETIC $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

682

Median for Otolaryngology: 297

Drug cost

$4,984

Median for Otolaryngology: $6,314

Branded share of claims

21.3%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 94 $1,442
Doxycycline Hyclate Generic 129 $1,014
Ondansetron Odt Ondansetron Brand 104 $548
Methylprednisolone Generic 89 $529
Mupirocin Generic 70 $509
Acyclovir Generic 108 $459
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 27 $204
Diazepam Generic 36 $149
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 14 $116
Prednisone Generic 11 $15

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
  • MERZ NORTH AMERICA, INC. $2,209
$2,209 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $284
$284 — —
DYSPORT
  • Galderma Laboratories, L.P. $158
$158 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery Within the Head and Neck in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record